Abstract
Invariant natural killer T (iNKT) cells display important properties that could bridge the innate and adaptive immunity, and they have been shown to play key roles in cancer immunotherapy. However, administration of iNKT cell agonist αGalCer fails to induce sustained antitumor immunity due to the rapid anergy induction after an initial strong activation. To this end, we have designed a recombinant CD1d protein that is fused to an anti-TAA scFv, which is able to recruit iNKT cells to the tumor site and induce tumor regression. Importantly, recombinant CD1d fusion proteins loaded with α-GalCer demonstrated sustained activation of iNKT cells upon repeated injections and superior tumor control, as compared to α-GalCer treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Salio M, Silk JD, Jones EY, Cerundolo V (2014) Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol 32:323–366. https://doi.org/10.1146/annurev-immunol-032713-120243
Zhang L, Tschumi BO, Corgnac S, Ruegg MA, Hall MN, Mach JP, Romero P, Donda A (2014) Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. J Immunol 193(4):1759–1765. https://doi.org/10.4049/jimmunol.1400769
Fujii SI, Shimizu K (2019) Immune networks and therapeutic targeting of iNKT cells in cancer. Trends Immunol 40(11):984–997. https://doi.org/10.1016/j.it.2019.09.008
Nair S, Dhodapkar MV (2017) Natural killer T cells in cancer immunotherapy. Front Immunol 8:1178. https://doi.org/10.3389/fimmu.2017.01178
Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS (2009) Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119(6):1524–1536. https://doi.org/10.1172/JCI37869
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS (2020) Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med 26(11):1686–1690. https://doi.org/10.1038/s41591-020-1074-2
Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115(9):2572–2583. https://doi.org/10.1172/JCI24762
Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A (2008) Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest 118(3):994–1005. https://doi.org/10.1172/JCI33249
Corgnac S, Perret R, Derre L, Zhang L, Stirnemann K, Zauderer M, Speiser DE, Mach JP, Romero P, Donda A (2013) CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother 62(4):747–760. https://doi.org/10.1007/s00262-012-1381-7
Corgnac S, Perret R, Zhang L, Mach JP, Romero P, Donda A (2014) iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. J Immunother Cancer 2(1):39. https://doi.org/10.1186/s40425-014-0039-8
Zhang L, Donda A (2017) Alpha-Galactosylceramide/CD1d-antibody fusion proteins redirect invariant natural killer T cell immunity to solid tumors and promote prolonged therapeutic responses. Front Immunol 8:1417. https://doi.org/10.3389/fimmu.2017.01417
Veerapen N, Kharkwal SS, Jervis P, Bhowruth V, Besra AK, North SJ, Haslam SM, Dell A, Hobrath J, Quaid PJ, Moynihan PJ, Cox LR, Kharkwal H, Zauderer M, Besra GS, Porcelli SA (2018) Photoactivable glycolipid antigens generate stable conjugates with CD1d for invariant natural killer T cell activation. Bioconjug Chem 29(9):3161–3173. https://doi.org/10.1021/acs.bioconjchem.8b00484
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Zhang, L., Donda, A. (2021). Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins. In: Liu, C. (eds) Invariant Natural Killer T-Cells. Methods in Molecular Biology, vol 2388. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1775-5_16
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1775-5_16
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1774-8
Online ISBN: 978-1-0716-1775-5
eBook Packages: Springer Protocols